KRAS and cancer: In addition, we provide a molecular basis for how Hh signals induce re-expression of KRAS in cells treated with a KRASG12C inhibitor, implying that combined treatment of KRASG12C inhibitors and Hh signal inhibitors may overcome acquired resistance in cancer patients harboring KRASG12C.